byiShook Opinion
Nov 25, 2024 - 11:05
Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. The post Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops appeared first on Investor's Business Daily.
Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing.
The post Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops appeared first on Investor's Business Daily.